


This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1. (Previously presented) A compound of the formula



(I)

wherein D, E, F, G, L, T, W, X, Y and Z are each, independently, N or CH;

U is N and U is single bonded to both carbons adjacent to it in the nitrogen containing ring of which it is a member;

A is (CH₂)_m wherein m is zero and the dashed lines attached to A are absent;

R¹ and R² are selected, independently, from hydrogen, (C₁-C₆) alkyl optionally substituted with from one to seven fluorine atoms, cyano, -OR⁹, and -CONHR¹⁰;

R³ and R⁴ are selected, independently, from hydrogen, halo, (C₁-C₆) alkyl optionally substituted with from one to seven fluorine atoms, cyano, hydroxy, -CONHR¹¹, -OR¹², -NR¹³R¹⁴ and -COR¹⁵;

R⁵ and R⁶ are selected, independently, from hydrogen, halo, (C₁-C₆) alkyl optionally substituted with from one to seven chlorine atoms, cyano, hydroxy, -CONHR¹⁶, -OR¹⁷, -NR¹⁸R¹⁹, and -COR²⁰;

R⁷ is hydrogen, (C₁-C₆)alkyl optionally substituted with from one to seven fluorine atoms, or aryl selected from phenyl and naphthyl, wherein said aryl can be optionally substituted with from one to three substituents independently selected from (C₁-C₄) alkyl optionally substituted with from one to three fluorine atoms, (C₁-C₄) alkoxy optionally substituted with from one to three fluorine atoms, cyano, nitro, halo, hydroxy, amino, (C₁-C₄) alkylamino, di[(C₁-C₆)alkyl] amino, (C₁-C₄) amidoamino and (C₁-C₄) alkanoyl;

R⁸ is selected from hydrogen, cyano, (C₁-C₆) alkyl optionally substituted with from one to seven fluorine atoms, -OR⁹, and -CONHR¹⁰;

R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁶, R¹⁷, R¹⁸ and R¹⁹ are selected, independently, from hydrogen, (C₁-C₆)alkyl optionally substituted with from one to seven fluorine atoms, and aryl, wherein

said aryl is selected from phenyl and naphthyl, and wherein said aryl can optionally be substituted with one or more substituents independently selected from (C₁-C₄) alkyl optionally substituted with from one to three fluorine atoms, (C₁-C₄) alkoxy optionally substituted with from one to three fluorine atoms, cyano, nitro, halo, hydroxy, amino, (C₁-C₄) alkylamino, di[(C₁-C₆)alkyl] amino, (C₁-C₄) amidoamino and (C₁-C₄) alkanoyl; R¹⁵ and R²⁰ are selected, independently, from NHR²¹ and the group of radicals listed in the definition of R⁹ through R¹⁹; and

R²¹ is selected from the group of radicals listed in the definition of R⁹ through R¹⁹;

or a pharmaceutically acceptable salt thereof,

with the proviso that ring D, E, F, G, L and ring T, W, X, Y, and Z are each independently pyrimidyl, or phenyl rings.

2. (Cancelled).

3. (Original) A compound according to claim 1, wherein both R¹ and R² are hydrogen.

4. (Original) A compound according to claim 1, wherein R¹ and R² are selected, independently, from hydrogen and (C₁-C₆)alkyl.

5-11. (Cancelled)

12. (Original) A compound according to claim 1 which is in the Z (cis) configuration with respect to the cyclopropyl ring.

13. (Previously presented) A compound according to claim 1 wherein the compound is:

[Z](+/-)N-{2-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-1-ylmethyl]-cyclopropylmethyl}-2,6-dimethyl-benzamide;

[Z](+/-)N-{2-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-1-ylmethyl]-cyclopropylmethyl}-4-chloro-benzamide;

[Z](+/-)N-{2-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-1-ylmethyl]-cyclopropylmethyl}-2,4,6-trimethyl-benzamide;

[Z](+/-)N-{2-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-1-ylmethyl]-cyclopropylmethyl}-3,4-dimethyl-benzamide;

[Z](+/-)N-{2-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-1-ylmethyl]-cyclopropylmethyl}-3,5-dimethoxy-benzamide;

[Z](+/-)N-{2-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-1-ylmethyl]-cyclopropylmethyl}-3-fluoro-benzamide;

[Z](+/-)N-{2-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-1-ylmethyl]-cyclopropylmethyl}-2-methyl-benzamide;

[Z](+/-)N-{2-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-1-ylmethyl]-cyclopropylmethyl}-2,3-dimethyl-benzamide;

[Z](+/-)N-{2-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-1-ylmethyl]-cyclopropylmethyl}-3,4-dimethoxy-benzamide;

[Z](+/-)N-{2-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-1-ylmethyl]-cyclopropylmethyl}-3,4,5-trimethoxy-benzamide;

[Z](+/-)N-{2-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-1-ylmethyl]-cyclopropylmethyl}-4-fluoro-benzamide;

[Z](+/-)N-{2-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-1-ylmethyl]-cyclopropylmethyl}-3-chloro-benzamide;

[Z](+/-)N-{2-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-1-ylmethyl]-cyclopropylmethyl}-4-trifluoromethyl-benzamide;

[Z](+/-)N-{2-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-1-ylmethyl]-cyclopropylmethyl}-3-cyano-benzamide;

[Z](+/-)N-{2-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-1-ylmethyl]-cyclopropylmethyl}-2,6-dimethyl-benzamide;

[Z](+/-)N-{2-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-1-ylmethyl]-cyclopropylmethyl}-2,4-difluoro-benzamide;

[Z](+/-)N-{2-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-1-ylmethyl]-cyclopropylmethyl}-2,3-difluoro-benzamide;

[Z](+/-)N-{2-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-1-ylmethyl]-cyclopropylmethyl}-2-trifluoromethyl-benzamide;

[Z](+/-)N-{2-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-1-ylmethyl]-cyclopropylmethyl}-2,5-dichloro-benzamide;

[Z](+/-)N-{2-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-1-ylmethyl]-cyclopropylmethyl}-2,3-dichloro-benzamide;

[Z](+/-)N-{2-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-1-ylmethyl]-cyclopropylmethyl}-2,4-dimethyl-benzamide;

[Z](+/-)N-{2-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-1-ylmethyl]-cyclopropylmethyl}-3-chloro-2-fluoro-benzamide;

[Z](+/-)N-{2-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-1-ylmethyl]-cyclopropylmethyl}-2-chloro-4-fluoro-benzamide;

[Z](+/-)N-{2-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-1-ylmethyl]-cyclopropylmethyl}-2,4-dichloro-benzamide; and

N-{2-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-1-ylmethyl]-cyclopropylmethyl}-4-diethylamino-benzamide.

14. (Original) A compound according to claim 1 wherein R¹ and R² are selected, independently, from hydrogen, methyl, cyano, trifluoromethyl and trifluoromethoxy.

15. (Previously presented) A pharmaceutical composition for treating a disorder or condition selected from psychotic disorders, and Parkinson's disease in a mammal, comprising an amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition, and a pharmaceutically acceptable carrier.

16. (Previously presented) A method of treating a disorder or condition selected from psychotic disorders, and Parkinson's disease in a mammal, comprising administering to said mammal an amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition.

17.-22. (Cancelled)

23. (Original) A method according to claim 16 wherein the disorder or condition being treated is a psychotic disorder or condition.

24.-25. (Cancelled)

26. (Original) A method according to claim 16 wherein the disorder or condition being treated is Parkinson's disease.

27.-32. (Cancelled)

33. (Previously presented) A compound according to claim 1 wherein the compound is:

[Z](+/-)2,6-Dimethyl-N-{2-[4-(3-trifluoromethyl-phenyl)-piperazin-1-ylmethyl]-cyclopropylmethyl}-benzamide; and

[E](+/-)-2,6-Dimethyl-N-{2-[4-(3-trifluoromethyl-phenyl)-piperazin-1-ylmethyl]-
cyclopropylmethyl}-benzamide.